EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase I)

Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study

Thomas Vanassche, Rachel P Rosovsky, Fares Moustafa, Harry R Büller, Annelise Segers, Indu Patel, Minggao Shi, Naoki Miyoshi, Venkatesh Mani, Zahi Fayad, Dominique Stephan, Jeannot Schmidt und 5 weitere

Journal of Thrombosis and Haemostasis · 2023

DOI: 10.1016/j.jtha.2023.04.037 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von Thomas Vanassche und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Sciences, University Hospitals Leuven, Leuven, Belgium. Electronic address: Thomas.vanassche@uzleuven.be. Hauptthemen laut MEDLINE: Carboxypeptidase B2, Pulmonary Embolism. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: FWO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The optimal treatment of intermediate-risk pulmonary embolism (PE) in hemodynamically stable patients remains unknown. Fibrinolytics reduce the risk of hemodynamic deterioration but increase bleeding risk. DS-1040, an inhibitor of thrombin-activatable fibrinolysis inhibitor, enhanced endogenous fibrinolytic activity without increasing bleeding risk in preclinical studies. OBJECTIVES: To evaluate the tolerability and explore the efficacy of DS-1040 in patients with acute PE. METHODS: In this multicenter, randomized, double-blind, placebo-controlled study, ascending doses of intravenous DS-1040 (20-80 mg) or placebo were added to enoxaparin (1 mg/kg twice daily) in patients with intermediate-risk PE. The primary endpoint was the number of patients with major or clinically relevant nonmajor bleeding. The percentage change in thrombus volume and right-to-left ventricular dimensions, assessed using quantitative computed tomography pulmonary angiography, at baseline and after 12 to 72 hours were used to explore the efficacy of DS-1040. RESULTS: Of 125 patients with all available data, 38 were randomized to placebo and 87 to DS-1040. The primary endpoint occurred in 1 patient in the placebo group (2.6%) and 4 patients who received DS-1040 (4.6%). One subject experienced major bleeding (DS-1040 80 mg group); no fatal or intracranial bleeding occurred. Thrombus volume was 25% to 45% lower after infusion, with no differences between the DS-1040 and placebo groups. There was no difference in the change from baseline right-to-left ventricular dimensions between the DS-1040 and placebo groups. CONCLUSION: In patients with acute PE, adding DS-1040 to standard anticoagulation was not associated with an increase in bleeding but did not improve thrombus resolution or right ventricular dilation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carboxypeptidase B2Pulmonary EmbolismHumansFibrinolytic AgentsAnticoagulantsThrombolytic TherapyHemorrhage

Stichwörter der Autor:innen

fibrinolysislow-molecular–weight heparinpulmonary embolismthrombin-activatable fibrinolysis inhibitorthrombolytic therapy

Substanzen

Fibrinolytic AgentsCarboxypeptidase B2Anticoagulants

Autor:innen und Institutionen

  • Department of Cardiovascular Sciences, University Hospitals Leuven, Leuven, Belgium. Electronic address: Thomas.vanassche@uzleuven.be.
  • Thrombosis Research, Division of Hematology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Emergency Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France; Université Clermont Auvergne, Clermont-Ferrand, France.
  • Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.
  • Itreas, Amsterdam, the Netherlands.
  • Clinical Development, Daiichi Sankyo, Basking Ridge, New Jersey, USA.

Förderung

  • FWO

Zitieren

APA

Vanassche, T., Rosovsky, R. P., Moustafa, F., Büller, H. R., Segers, A., Patel, I., Shi, M., Miyoshi, N., Mani, V., Fayad, Z., Stephan, D., Schmidt, J., Grosso, M. A., Tapson, V. F., Verhamme, P., Huisman, M. V., & of the DS-1040 Study Group (2023). Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.04.037

Vancouver

Vanassche T, Rosovsky RP, Moustafa F, Büller HR, Segers A, Patel I, et al. Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.04.037

BibTeX
@article{Vanassche2023,
  author = {Vanassche, Thomas and Rosovsky, Rachel P and Moustafa, Fares and Büller, Harry R and Segers, Annelise and Patel, Indu and Shi, Minggao and Miyoshi, Naoki and Mani, Venkatesh and Fayad, Zahi and Stephan, Dominique and Schmidt, Jeannot and Grosso, Michael A and Tapson, Victor F and Verhamme, Peter and Huisman, Menno V and of the DS-1040 Study Group, of the DS-1040 Study Group},
  title = {Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  doi = {10.1016/j.jtha.2023.04.037}
}
Kostenlos starten →